Sensitivity of CYP1A1 mRNA inducibility by dioxin is the same in cyp1a2(+/+) wild type and cyp1a2(-/-) null mutant mice

Biochemical Pharmacology

Volumn 54, Issue 10, 1997, Pages 1127-1131

  Liang, H C Leonard ^a   McKinnon, Ross A ^a   Nebert, Daniel W ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

aminolevulinic acid synthase; Ah gene battery; AH receptor; CYP1A1 induction; CYP1A2; Dioxin pharmacokinetics; Experimental porphyria; Halogenated hydrocarbons; Knockout mouse line

Indexed keywords

AMINOLEVULINIC ACID; AROMATIC HYDROCARBON; AROMATIC HYDROCARBON RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; LIVER METABOLISM; MAMMAL; MOUSE; MUTANT; NONHUMAN; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENZYME INDUCTION; MICE; MICE, KNOCKOUT; POLYMORPHISM, GENETIC; RNA, MESSENGER; TETRACHLORODIBENZODIOXIN;

EID: 0030709320     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00263-3     Document Type: Article

References (35)

1. Poland A, Glover E. 2,3,7,8-Tetrachlorodibenzo-p-dioxin a potent inducer of δ-aminolevulinic acid synthetase . Science. 179:1973;476-477.
2. Poland A, Glover E. Chlorinated dibenzo-p-dioxins potent inducers of δ-aminolevulinic acid synthetase and aryl hydrocarbon hydroxylase II. A study of the structure-activity relationship . Mol Pharmacol. 9:1973;736-747.
3. Nebert DW. The Ah locus genetic differences in toxicity, cancer, mutation and birth defects . Crit Rev Toxicol. 20:1989;153-174.
4. Swanson HI, Bradfield CA. The AH-receptor genetics, structure and function . Pharmacogenetics. 3:1993;213-230.
5. Nebert DW, Puga A, Vasiliou V. Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer and in signal transduction. Ann NY Acad Sci. 685:1993;624-640.
6. Birnbaum LS. The mechanism of dioxin toxicity relationship to risk assessment . Environ Health Perspect. 102:1994;157-167.
7. Jones KG, Sweeney GD. Dependence of the porphyrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin upon inheritance of aryl hydrocarbon hydroxylase responsiveness. Toxicol Appl Pharmacol. 53:1980;42-49.
8. Urquhart AJ, Elder GH, Roberts AG, Lambrecht RW, Sinclair PR, Bement WJ, Gorman N, Sinclair JA. Uroporphyria produced in mice by 20-methylcholanthrene and 5-aminolaevulinic acid. Biochem J. 253:1988;357-362.
9. Greig JB, Francis JE, Kay SJE, Lovell DP, Smith AG. Incomplete correlation of 2,3,7,8-tetrachlorodibenzo-p-dioxin hepatotoxicity with Ah phenotype in mice. Toxicol Appl Pharmacol. 74:1984;17-25.
10. Smith AG, Francis JE. Genetic variation of iron-induced uroporphyria in mice. Biochem J. 291:1993;29-35.
11. Smith AG, Francis JE. Synergism of iron and hexoachlorobenzene inhibits hepatic uroporphyrinogen decarboxylase in inbred mice. Biochem J. 241:1983;909-913.
12. Alleman MA, Koster JF, Wilson JHP, Edixhoven-Bosdijk A, Slee RG, Kroos MJ, von Eijk HG. The involvement of iron and lipid peroxidation in the pathogenesis of HCB-induced porphyria. Biochem Pharmacol. 34:1985;161-166.
13. Hahn ME, Gasiewicz TA, Linko P, Goldstein JA. The role of the Ah locus in hexachlorobenzene-induced porphyria studies in congenic C57BL/6J mice . Biochem J. 254:1988;245-254.
14. Jacobs JM, Sinclair PR, Bement WJ, Lambrecht RW, Sinclair JF, Goldstein JA. Oxidation of uroporphyrinogen by methylcholanthrene-induced P-450. Biochem J. 258:1989;247-253.
15. Voorman R, Aust SD. Inducers of cytochrome P-450d influence on microsomal catalytic activities and differential regulation by enzyme stabilization . Arch Biochem Biophys. 262:1988;76-84.
16. Miller DM, Aust AE, Voorman R, Aust SD. Inhibition of 2-aminofluorene mutagenesis in bacteria by inducers of cytochrome P450d. Carcinogenesis. 9:1988;327-329.
17. Jacobs JM, Sinclair PR, Lambrecht RW, Sinclair JF, Jacobs NJ. Role of inducer binding in cytochrome P-450 IA2-mediated uroporphyrinogen oxidation. J Biochem Toxicol. 5:1990;193-199.
18. Van Birgelen APJM, Fase KM, van der Kolk J, Poiger H, Brouwer A, Seinen W, van den Berg M. Synergistic effect of 2,2′, 4,4′, 5,5′-hexachlorobiphenyl and 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic porphyrin levels in the rat. Environ Health Perspect. 104:1996;550-557.
19. Kuroki J, Koga N, Yoshimura H. High affinity of 2,3,4,7,8-pentachlorodibenzofuran to cytochrome P-450 in the hepatic microsomes of rats. Chemosphere. 15:1986;731-738.
20. Voorman R, Aust SD. Specific binding of polyhalogenated aromatic hydrocarbon inducers of cytochrome P450d to the cytochrome and inhibition of its estradiol 2-hydroxylase activity. Toxicol Appl Pharmacol. 90:1987;69-78.
21. 125I]2-Iodo-3,7,8-tetrachlorodibenzo-p-dioxin-binding species in mouse liver induced by agonists for the Ah receptor characterization and identification . Mol Pharmacol. 36:1989;113-120.
22. 125I]2-iodo-3,7,8-tetrachlorodibenzo-p-dioxin by the administration of agonist for the Ah receptor. Mol Pharmacol. 36:1989;121-127.
23. Kedderis LB, Diliberto JJ, Linko P, Goldstein JA, Birnbaum LS. Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat biliary excretion and induction of cytochromes CYP1A1 and CYP1A2 . Toxicol Appl Pharmacol. 111:1991;163-172.
24. Kedderis LB, Mills JJ, Andersen ME, Birnbaum LS. A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat tissue distribution and CYP1A induction . Toxicol Appl Pharmacol. 121:1993;87-98.
25. Liang HC, Li H, McKinnon RA, Duffy JJ, Potter SS, Puga A, Nebert DW. Cyp1a2(-/-) null mutant mice develop normally, but show deficient drug metabolism. Proc Natl Acad Sci USA. 93:1996;1671-1676.
26. Nebert DW, Duffy JJ. How knockout mouse lines will be used to study the role of drug-metabolizing enzymes and their receptors during reproduction, development, and environmental toxicity, cancer and oxidative stress. Biochem Pharmacol. 53:1997;249-254.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
28. 3-450 cDNA nucleotide and amino acid sequences . J Biol Chem. 259:1984;10705-10713.
29. Burcham T, Scan analysis: the densitometer for the Macintosh. Biosoft, Ferguson, MO, 1989.
30. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2 sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression . Mol Endocrinol. 3:1989;1399-1408.
31. Shimada T, Yun CH, Hiroshi Y, Gautier JC, Beaune PH, Guengerich FP. Characterization of human lung microsomal cytochrome P4501A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol. 41:1992;856-864.
32. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and acetyltransferase phenotype in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 2:1992;116-127.
33. Tang BK, Zhou Y, Kalow W. Caffeine as a probe for CYP1A2 activity potential influence of renal factors on urinary phenotypic trait measurements . Pharmacogenetics. 4:1994;117-124.
34. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms effects on risk of toxicity and cancer . DNA Cell Biol. 15:1996;273-280.
35. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism studies with recombinant Chinese hamster cells and analyses in human populations . Pharmacogenetics. 5:1995;S65-S69.